August 08, 2008

Faegre & Benson Represents Affinity BioReagents in Acquisition by Thermo Fisher Scientific

Faegre & Benson LLP recently represented Affinity BioReagents, Inc., a Golden, Colorado-based company, in its acquisition by Thermo Fisher Scientific Inc.

With an offering of more than 35,000 reagents, Affinity BioReagents is a leading provider of antibodies, peptides and proteins for life science research. Thermo Fisher Scientific (NYSE: TMO) is a leader in the international health and science community, with over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies.

John R. Marcil, a corporate partner in the firm's Boulder office, served as lead attorney on the deal with support from Matt Stamski.

Faegre Baker Daniels 网站使用 Cookie 来提升您的浏览体验。